Navigation Links
New Data On the Probiotic Strain Bifantis Shows Anti-Inflammatory,Properties and Increased Health Benefits

- Bifantis shows ability to limit inflammation in models of arthritis and Salmonella infection, according to data presented at Digestive Disease Week -

WASHINGTON, May 21, 2007 /PRNewswire/ -- The biotechnology company Alimentary Health today announced results from two studies that demonstrate the anti-inflammatory activity of a natural probiotic bacterial strain of human origin, Bifantis(R) (Bifidobacterium infantis 35624), in models of arthritis and Salmonella infection. Data from these studies were presented this week at the 38th annual Digestive Disease Week (DDW) conference taking place in Washington D.C.

The inflammatory response is a key part of the immune system's battle against invaders, but in certain conditions and diseases, it can do more harm than good by injuring healthy tissue. Inflammation is associated with a variety of conditions, such as inflammatory bowel disease, arthritis, cardiovascular disease, diabetes, Alzheimer's disease and more. Bifantis has previously been shown to modulate the inflammatory response in a clinical trial in irritable bowel syndrome. The results announced this week demonstrate that the anti-inflammatory effects of Bifantis are not restricted to the gastrointestinal tract.

"Inflammation is a major factor in a number of chronic diseases, which affect millions of people," said Barry Kiely, Chief Executive Officer, Alimentary Health and an early investigator of the probiotic effects of Bifantis. "Data continue to show that Bifantis has anti-inflammatory activity, which may be useful in the management of inflammation-linked diseases."

In one of the studies released today, four bacterial strains were fed to mice. Of these four strains, researchers determined that only Bifantis delayed the onset of artificially induced arthritis and resulted in less severe arthritic symptoms. This study represents some of the latest work assessing the link between diet i
'"/>




Page: 1 2 3

Related medicine technology :

1. New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus
2. New Flu Vaccine From PepTcell Could Provide Immunity Against All Strains of Influenza Virus
3. NanoViricides Drugs Found To Be Highly Effective Against Most Recent Strain of the H5N1 Avian Flu Virus
4. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
7. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
8. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
9. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
10. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
11. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
Post Your Comments:
(Date:12/4/2009)... WASHINGTON, Dec. 4 Chemistry World recently highlighted ... Research and Manufacturers of America ( PhRMA ) that ... and related conditions. ,, The report found that ... antivirals. These drugs are either in human clinical trials or ...
(Date:12/4/2009)... (NYSE Amex: PIP ), a biodefense company ... announced today that the Company is presenting results ... in an inhalation anthrax model in the New ... being presented during an oral session at the ...
(Date:12/4/2009)... OrthoAccel Technologies, Inc., developers of the AcceleDent ... enhance orthodontics, announced the availability of a new ... , a leader in professional education for many ... focuses on patient views about orthodontic treatment, a ...
Breaking Medicine Technology:U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4GenVec Announces Third Quarter 2009 Results Conference Call 14630 1GenVec Announces Third Quarter 2009 Results Conference Call 14630 2Osteotechs MagniFuse 28TM 29 Technology Used in First U S Surgery 5781 1Osteotechs MagniFuse 28TM 29 Technology Used in First U S Surgery 5781 2Osteotechs MagniFuse 28TM 29 Technology Used in First U S Surgery 5781 3Osteotechs MagniFuse 28TM 29 Technology Used in First U S Surgery 5781 4Santaris Pharma A S Expands Executive Team Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA targeted Drug Develop 5776 1Santaris Pharma A S Expands Executive Team Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA targeted Drug Develop 5776 2Santaris Pharma A S Expands Executive Team Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA targeted Drug Develop 5776 3Santaris Pharma A S Expands Executive Team Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA targeted Drug Develop 5776 4
(Date:12/6/2009)... College of Wisconsin, in Milwaukee, found a substantial variation ... disease complications in children. Barriers to its use on ... identified. The study led by Amanda M. Brandow, ... College and Children,s Research Institute at the Children,s Hospital ... of Hematology meeting Dec. 7, 2009, in New Orleans. ...
(Date:12/6/2009)... 2009 A new study provides welcome news for ... thromboembolism (VTE). , The condition is estimated to ... occurs when an abnormal clot forms in a vein ... swelling. In some cases, the clot may detach from ... to the lungs, causing a potentially fatal condition known ...
(Date:12/5/2009)... three-drug combination has shown in a phase 1/2 ... in the treatment of patients newly diagnosed with multiple ... marrow, say researchers from Dana-Farber Cancer Institute. , Partial ... 66 patients treated with the drug combination in the ... partial response rate" in the phase 2 population, reports ...
(Date:12/5/2009)... --In Youngest Babies, This Type of Blood Cancer Is ... Dec. 5 Pediatric oncologists have identified specific genes, ... drive an often-fatal form of leukemia in infants. By ... better predict which infants may benefit from particular treatments. ...
(Date:12/5/2009)... Technology Center helps companies develop and test their cleaning processes. The ... variety of industries and solve problems for customers relating to cleaning ... ... 5, 2009 -- Midbrook, Inc , a Jackson, MI-based company, ...
Breaking Medicine News(10 mins):Health News:New study finds barriers to pain treatment in children with sickle cell disease 2Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3
... healthcare real estate company providing ... hospitals and physicians ... CHARLOTTE, N.C., Jan. 23 Cogdell Spencer Inc.,(NYSE: ... agreement,to acquire 100 percent of the stock of Marshall Erdman ...
... [Brown University] When faced with even a ... fewer women receive these potentially life-saving breast cancer ... University and Harvard Medical School researchers. , In ... insurance co-payments and mammography rates, researchers found that ...
... 23 Pennsylvania,AFL-CIO President William George and Secretary ... decisions by,Representatives John Peterson, Joseph Pitts, and William ... millions of children in,families hit hardest by our ... in the face of a severe economic downturn,Representatives ...
... Jan. 23 Johnson & Johnson,Pharmaceutical Research & ... Drug Application (NDA) to the U.S. Food and ... an investigational oral analgesic for the relief of ... American Pain Foundation, more than 25 million,Americans experience ...
... Jan. 23 Boston Scientific (NYSE: BSX ),today ... Chief,Medical and Scientific Officer, on an article in the ... and Drug-Eluting Stents for,Off-Label Indications.", "The analysis from ... in today,s New England Journal of Medicine is the ...
... went five years without anti-rejection drugs , , WEDNESDAY, ... transplant recipients to stop taking powerful immunosuppressive drugs are ... in the development of the transplant field is to ... the lifesaving benefit of the transplant without the costs ...
Other Medicine News:Health News:Cogdell Spencer Inc. Announces Merger with Marshall Erdman and Associates 2Health News:Cogdell Spencer Inc. Announces Merger with Marshall Erdman and Associates 3Health News:Cogdell Spencer Inc. Announces Merger with Marshall Erdman and Associates 4Health News:Cogdell Spencer Inc. Announces Merger with Marshall Erdman and Associates 5Health News:Health insurance co-payments deter mammography use 2Health News:Health insurance co-payments deter mammography use 3Health News:Pennsylvania AFL-CIO Decries Shameful Votes Again by Representatives John Peterson, Joe Pitts and Bill Shuster, Against Children's Health Care 2Health News:New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets 2Health News:New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets 3Health News:New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets 4Health News:Boston Scientific Comments on New England Journal of Medicine Article 2Health News:Boston Scientific Comments on New England Journal of Medicine Article 3Health News:New Therapies Could Change Organ Transplants 2Health News:New Therapies Could Change Organ Transplants 3
Used for complex diagnostic and interventional procedures....
... St. Jude Medical offers a ... for use with percutaneous catheter ... of intravascular catheters. Our diagnostic ... lengths and incorporate a proprietary ...
... VISION Coronary Stent System is Guidant's first ... stents. Cobalt chromium is stronger and more ... chromium stent can have similar strength and ... with struts that are only .0032" thick. ...
... The CYPHER Sirolimus-eluting Coronary ... antiproliferative drug, called "sirolimus", a ... stent delivery platform. Upon placement, ... wall and impedes the process ...
Medicine Products: